Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with rhGM-CSF and Peginterferon alfa-2b in Metastatic Thymic Epithelial Tumors
NCT04517539Phase 2Unknown
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim, peginterferon alfa-2b in thymic epithelial tumor (TET), sponsored by Fudan University Shanghai Cancer Center. Status: unknown.
02
Drugs
sargramostimpeginterferon alfa-2b
03
Conditions
thymic epithelial tumor (TET)
Beyond the preview
Go deeper on NCT04517539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517539.